The patients in this study who will receive
RO5509554 alone include those with pigmented villonodular synovitis,
tenosynovial giant cell tumor, soft-tissue sarcoma, malignant mesothelioma,
ovarian cancer, endometrial cancer, breast cancer, and pancreatic cancer.
RO5509554 will be given with paclitaxel in patients with HER2-negative breast
cancer.
http://www.mskcc.org/cancer-care/trial/14-086
No comments:
Post a Comment